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Several elegant studies, summarised in their review by the
Coagulation in Liver Disease Study Group, have helped in
changing the paradigm of bleeding related to liver disease, from
abnormal coagulation proﬁle to haemostatic alterations second-
ary to portal hypertension, endogenous heparinoids, sepsis, and
renal failure [1]. However, one of the key omissions in this
respect is the role of anemia in worsening the haemorrhagic
tendency of liver dysfunction. Anemia is common in individuals
with chronic liver disease and is likely to be of multifactorial
etiology including folate deﬁciency, hypersplenism, hemodilu-
tion, haemolysis, bone marrow suppression due to viruses or
ethanol, renal insufﬁciency, and, most importantly, variceal
bleeding. How anemia would worsen the bleeding tendency in
these patients has not been directly studied but several factors
are responsible.
Firstly, anemia worsens the hyperdynamic circulation, the key
pathogenetic feature of portal hypertension [2]. This is possibly
due to the reduction in blood viscosity but some evidence for
the role of the vasodilator nitric oxide (NO) has also been sug-
gested [3]. As demonstrated in experimental animals, NO may
also play a central role in the systemic and splanchnic vasodila-
tion associated with portal hypertension with increased vascular
responses to speciﬁc inhibitors of NO biosynthesis [2]. Secondly,
there is evidence that red blood cells not only have passive, rhe-
ological effects on blood coagulation but also actively stimulate
thrombin generation [4]. The best example of the haemostatic
role of red cells is represented by the increased thrombotic ten-
dency of polycythemia and erythropoiesis-stimulating agents.
Interestingly, a small prospective study of 42 patients with
chronic anemia (unrelated to liver disease) shown an unex-
plained improvement in the activated partial thromboplastin
time but not in the prothrombin time measured before and after
the transfusion of packed red cells [5].
By far, the most likely explanation for the bleeding tendency
with anemia is the effect of red cells on platelet function. Red cells
release adenosine diphosphate which promotes platelet aggrega-
tion and also stimulates platelet synthesis of thromboxane A2, a
key platelet activator during vessel injury. Haemoglobin could
also play an important role because of its high afﬁnity for NO.
The reduced NO scavenging, caused by the reduced level of hae-
moglobin in anemia, activates guanylyl cyclase and further
impairs platelet aggregation. Moreover, in normal physiological
states, red cells, being the largest cells, tend to occupy the central
part of the vasculature, pushing the platelets nearer to the vessel
wall, where they are poised to respond to injury. In anemic states,
the concentration of platelets in proximity to the endothelium is
reduced thus affecting the haemostatic process. The beneﬁcial
effect of red cells on platelet function was ﬁrst reported by Duke
in 1910 but was conclusively proved by Hellem who examined
anemic patients with bleeding defects showing a decrease inJournal of Hepatology 2bleeding time (BT) upon transfusion of washed red cells [6]. This
observation has been more recently conﬁrmed, when improved
BT after red cell transfusions were observed in experimental and
clinical subjects with continued thrombocytopenia and in uremic
patients with bleeding tendency and normal platelet counts [7,8].
One of the possible negative arguments for these studies would be
the assessment of BT rather than further bleeding episodes, with
red cell replacement. BT is prolonged in cirrhotics to variable
extent, although the exact cause for this phenomenon has never
been explained, especiallywhen therewas no negative correlation
between platelet counts and BT, and an abnormal VonWillebrand
factor was not seen in these patients [9]. In this context, it is useful
to remember that BT is not just a measure of platelet function but
is also inﬂuenced by red cell volume, blood urea concentration,
and strength of the vascular connective tissue. Although platelet
dysfunction in liver disease has been experimentally shown to
be balanced by increased highly active VonWillebrand factor mul-
timers, the aforementioned remaining factors (especially correct-
able anemia), have not been considered [1].
Studies on a favourable outcome on bleeding with treatment
of anemia in liver disease are worthwhile, especially as similar
measures have hugely beneﬁted patients with renal impairment
treated with erythropoietin and intravenous iron. Homoncik and
colleagues have conducted a randomized, double-blind, placebo-
controlled trial of erythropoietin in 22 thrombocytopenic
patients with alcoholic liver cirrhosis and have found higher
platelet counts and platelet reactivity by ﬂow cytometry in these
patients with a more pronounced effect in presence of lower
platelet counts [10].
In summary, although ‘‘blood component’’ (plasma products)
transfusion may indeed be harmful in liver patients with bleeding
tendency, strong consideration should be made for ‘‘blood’’ trans-
fusion, despite its rare adverse effects. It is also worthwhile
assessing the response to iron replacement and/or erythropoietin
administration in selected patients (bearing in mind thrombotic
potential) on the bleeding risk associated with liver disease.
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Reply to Dr. Tachil:
We appreciate the interest of Dr. Thachil in our recently published
meeting report on coagulation disorders in patients with liver dis-
ease [1]. Dr. Thachil states that the anemia of liver disease may be
important in the bleeding manifestations in these patients, with
whichwe fully agree. The role of anemia was simply not discussed
during the 3rd International Symposium on Coagulopathy and
Liver disease, highlights of which were summarised in the meet-
ing report. Whereas the omission of the role of anemia in the con-
ference programme is the responsibility of us as conference
organisers, we havemade a case for the role of anemia in the coag-
ulopathy of liver disease in previous publications [2,3]. We fully
agree that red cells are important in the hemostatic process, in
particular due to the effects of red cells on platelet attachment
to the damaged vasculature in ﬂowing blood. In fact, experimental
evidence from us and others has indicated that anemia is a key
factor in platelet hypofunction studied in ex vivo experimental
models [2,4]. Furthermore, as also mentioned by Dr. Thachil, cor-
rection of anemia in patients with renal disease by red cell trans-
fusion or administration of erythropoietin appears to reduce
uremic bleeding. Nevertheless, we do believe clinical evidence
supports the concept of ‘rebalanced hemostasis’ in liver disease
[5]. More and more centers report that a large proportion of
patients can undergo a liver transplantation without any require-
ments for blood product transfusion despite persistent periopera-
tive anemia (reviewed in [5]).
The rebalanced hemostasis theory explains these observa-
tions by the presence of compensatory factors for thrombocyto-
penia (high levels of von Willebrand factor) and decreased
levels of procoagulant and antiﬁbrinolytic proteins (i.e.,
decreased levels of anticoagulant and proﬁbrinolytic proteins).
No compensatory factor for anemia appears present, although
as mentioned in our meeting report, platelet function in vivo
could be promoted by a reduced glycocalix on the vascular
endothelium. To our knowledge experimental data on a possible
role of reduced endothelial glycocalix in promoting platelet
function in the anemic and thrombocytopenic patient with cir-
rhosis are not available, but experiments testing this hypothesis
would be of interest.
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As discussed in the meeting report, bleeding episodes do
occur in patients with liver disease, and also during liver trans-
plantation severe bleeding can on occasion be encountered.
Reversal of anemia may thus be of beneﬁt for the patient with
liver disease by reducing bleeding risk, and we agree with Dr.
Thachil that clinical studies on this issue are worthwhile. We
have recently proposed outlines for clinical studies on the pre-
vention of bleeding or thrombosis in patients with liver disease
[5] and agree that randomised controlled studies on reduction
of bleeding during invasive procedures by red cell transfusion
or administration of erythropoietin and intravenous iron would
also be of interest. These studies, however, should carefully
assess potential risks associated with these therapeutic strate-
gies. We and others have recently demonstrated that transfusion
of red cell concentrates during liver transplantation is associated
with increased morbidity and mortality [6]. Accumulating clinical
and laboratory evidence suggests that a restrictive transfusion
policy, which includes acceptance of a low hematocrit, during
liver transplantation is safe and effective (reviewed in [5]). Trans-
fusion of red cell concentrates to patients with liver failure may
result in aggravation of portal hypertension, which may even par-
adoxically induce or facilitate bleeding. These effects demon-
strated both experimentally and clinically (reviewed in [7]) led
to recommendations that red cell transfusions be limited in var-
iceal bleeding with a target hemoglobin between 7 and 8 g/dl in
the Baveno V criteria [8]. One could argue that a slightly higher
value or use of a hematocrit target of 25% might better balance
between effective platelet rheology and portal pressure as the ini-
tial platelet plug probably plays some role in variceal bleeding
cessation, although pressure effects dominate.
The effects of red cell transfusion on hemostasis in the patient
with liver failure and portal hypertension are thus complex, and
clinical studies should therefore assess both efﬁcacy and safety.
In our opinion, current evidence suggest that a restrictive trans-
fusion policy, which includes restrictive use of red cell concen-
trates should be standard of care until randomised clinical
studies suggest otherwise. Administration of erythropoietin
may be a more attractive therapeutic strategy in patients with
liver disease, as an unwanted volume expansion is avoided.
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